Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer | Tuberculosis and Respiratory Diseases;: 93-97, 2009. | WPRIM

Main content 1 Search 2 Footer 3

+A A -A High contrast

Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer / 결핵및호흡기질환

Hee-Jung BAN; In-Jae OH; Kyu-Sik KIM; Jin-Yung JU; Yong-Soo KWON; Yu-Il KIM; Sung-Chul LIM; Young-Chul KIM.

Tuberculosis and Respiratory Diseases ; : 93-97, 2009.

Article in En | WPRIM | ID: wpr-52271

Responsible library: WPRO

ABSTRACT

ABSTRACT

No abstract available.

Subject(s)

Camptothecin; Recurrence; Small Cell Lung Carcinoma

Key words

Belotecan; Camptothecin; Small cell lung carcinoma; Relapse

Search on Google

Full text: 1 Index: WPRIM Main subject: Recurrence / Camptothecin / Small Cell Lung Carcinoma Language: En Journal: Tuberculosis and Respiratory Diseases Year: 2009 Type: Article

Search on Google

Full text: 1 Index: WPRIM Main subject: Recurrence / Camptothecin / Small Cell Lung Carcinoma Language: En Journal: Tuberculosis and Respiratory Diseases Year: 2009 Type: Article